Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
The new technique, audioplethysmography, can monitor a user’s heart rate and other physiological signals using headphones equipped with active noice canceling technology. It requires no additional sensors.
Robert Yeh, MD, detailed the importance of the pivotal AGENT IDE trial, which focused on the use of a paclitaxel-coated balloon to treat in-stent restenosis.
New data presented at TCT 2023 suggest the Evoque tricuspid valve replacement system could make a significant impact on the lives of patients with severe TR.
More than 5,000 women were interviewed about their eating habits from 1985 to 1991, and then researchers followed up with them 30 years later. The full study was published in Alzheimer’s and Dementia.
Even as TAVR continues to build momentum as the go-to treatment option for many patients, researchers are keeping a close eye on the long-term safety and effectiveness of SAVR.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
